Erste Asset Management Gmb H Sage Therapeutics, Inc. Transaction History

Erste Asset Management Gmb H

$11.9 Trillion
Q2 2025

A detailed history of Erste Asset Management Gmb H transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Erste Asset Management Gmb H holds 28,500 shares of SAGE stock, worth $247,380. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,500

Previous 28,500 -0.0%

Holding current value

$247,380

Previous $236 Million 10.51%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$7.02 - $13.08 $200,070 - $372,780	28,500 New	28,500 $208 Million
Q2 2022 Nov 26, 2024	SELL	$27.52 - $37.99 $192,640 - $265,930	-7,000 Reduced 19.72%	28,500 $935 Million
Q1 2022 Nov 22, 2024	SELL	$30.71 - $45.71 $153,550 - $228,550	-5,000 Reduced 14.93%	28,500 $977 Million
Q4 2021 Nov 22, 2024	SELL	$37.06 - $47.11 $611,490 - $777,315	-16,500 Reduced 57.89%	12,000 $510 Million
Q4 2020 Nov 22, 2024	BUY	$58.41 - $89.06 $864,468 - $1.32 Million	14,800 Added 79.14%	33,500 $2.92 Billion
Q3 2020 Nov 22, 2024	SELL	$41.13 - $62.45 $403,074 - $612,010	-9,800 Reduced 34.39%	18,700 $1.12 Billion
Q4 2019 Nov 22, 2024	SELL	$60.18 - $154.77 $589,764 - $1.52 Million	-9,800 Reduced 34.39%	18,700 $1.37 Billion
Q2 2019 Nov 22, 2024	SELL	$157.85 - $183.09 $726,110 - $842,214	-4,600 Reduced 11.86%	34,200 $6.17 Billion
Q1 2019 Nov 22, 2024	BUY	$89.33 - $163.65 $920,099 - $1.69 Million	10,300 Added 36.14%	38,800 $6.2 Billion
Q4 2018 Nov 26, 2024	BUY	$81.94 - $139.71 $573,580 - $977,970	7,000 Added 24.56%	35,500 $3.12 Billion

Others Institutions Holding SAGE

# of Institutions

219

Shares Held

50.2M

Call Options Held

790K

Put Options Held

440K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $516M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.

Account

Erste Asset Management Gmb H Sage Therapeutics, Inc. Transaction History